news-med.jpg

Nerina Coppini

Recent Posts

Aptuit's Collaboration with MGH Covered on OneNucleus Spring 2017 Newsletter

Our recent collaboration with Massachusetts General Hospital (MGH) on the identification and validation of novel targets in Gram-negative bacteria is covered in the Spring edition of OneNucleus Newsletter. Read the full article on page 8 with our expert, Antonio Felici.

Topics: Drug design and discovery, antibiotic resistance, Gram-negative bacteria, Partner Research Organization, Antibacterial Read More

Why We Need a Culture of International Collaboration to Fight Antibiotic Resistance

Read the article on antimicrobial resistance from our very own Antonio Felici, which was published in Bioscience Technology this month. Read full article from Bioscience Technology online site

Topics: Drug design and discovery, antibiotic resistance, Drug Discovery Read More

Aptuit Announces Alignment of Organizational Structure to Integrated Solution Delivery: Henning Steinhagen Appointed as President, Research and Development Operations

Greenwich, CT, April 6, 2017 – Jonathan Goldman, CEO of Aptuit LLC, announced today that Henning Steinhagen, PhD, has been named as President, Research and Development Operations. Henning will continue in his existing role of Site-Head at Aptuit, Verona, Italy whilst assuming oversight of Aptuit ...

Topics: Corporate, Partner Research Organization Read More

Pharma's Almanac on Aptuit's Collaboration with Bioversys

Nice coverage in Pharma's Almanac of Aptuit's collaboration with Bioversys. Aptuit in Bacteria Resistance Collaboration Drug development firm Aptuit has begun a joint collaboration with the Swiss biotech Bioversys that is aimed at the identification and validation of novel targets and molecules for ...

Topics: Drug design and discovery, antibiotic resistance Read More

Aptuit Selected as a Winner of Life Science Leader Global Award for Contract Drug Manufacturer in Multiple Categories

Greenwich, CT – March 13, 2017 - Aptuit, LLC today announced that the company has been selected as a winner of four Contract Manufacturer Organization (CMO) Leadership Awards by Life Science Leader magazine. Aptuit was selected from a survey of pharma and biopharma companies who had outsourced ...

Topics: Business, CMC, CMO award Read More

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens

Basel, Switzerland and Greenwich, CT – March 7, 2017 - Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address ...

Topics: Drug design and discovery, antibiotic resistance, Drug Discovery, Gram-negative bacteria, Partner Research Organization Read More

Dementia Discovery Fund Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes

The Dementia Discovery Fund announces the acquisition of a >500,000 compound, CNS-biased small molecule library The DDF and Aptuit enter into a strategic partnership to leverage the DDF library and Aptuit’s capabilities for dementia drug discovery London, Boston, Greenwich - February 28, 2017 – The ...

Topics: Drug design and discovery, hit discovery, Drug Discovery, dementia drug discovery, computational chemistry, compound logistics, assay development Read More

SAMDI Tech, Inc. and Aptuit Announce Drug Discovery Screening Partnership

CHICAGO, IL – February 7, 2017 – SAMDI Tech, Inc. and Aptuit, LLC are partnering to broaden their portfolio of assay development and high-throughput drug discovery services in Europe and North America. The partnership provides early-stage drug discovery researchers with access to SAMDI Tech’s ...

Topics: Strategy, Corporate, Business, Drug design and discovery Read More

Aptuit announces drug discovery collaboration with Massachusetts General Hospital (MGH) to identify novel treatments for Gram-negative infections

Greenwich, CT - January 24, 2017 - Aptuit, LLC today announced the start of a collaboration with the Molecular Surgical Laboratory of Massachusetts General Hospital (MGH), directed by Dr. Laurence Rahme, aimed at the identification and validation of novel targets in Gram-negative bacteria. Aptuit ...

Topics: Corporate, Drug design and discovery Read More

Chronos Therapeutics partners with Aptuit for addictive behaviour programmes

Oxford, UK - January 9, 2017 - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, announced that they have partnered with a subsidiary of Aptuit Holdings LLC (Aptuit) for services related to Chronos’ programme targeting ...

Topics: Corporate, Business Read More